Gene therapy doubles survival in recurrent glioblastoma

(University of Texas Health Science Center at San Antonio) An experimental gene therapy essentially doubled the overall survival of patients with recurrent glioblastoma compared to the current standard of care, a researcher said Oct. 1 at the Cancer Therapy &Research Center at The University of Texas Health Science Center at San Antonio.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Here, one of the leading researchers working on the biochemistry of senescent cells - and their relevance to aging - considers the state of development of senolytic therapies. These are treatments, largely small molecule drugs at this stage, but also including suicide gene therapies, immunotherapies, and more, that are capable of selectively destroying some fraction of the senescent cells present in old tissues. There is tremendous enthusiasm in the scientific and development communities for the potential to create significant degrees of rejuvenation via this approach. The results in mice are far and away more impressive a...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
In conclusion, the targeting tLyp-1 exosomes are successfully engineered, and can be used for gene therapy with a high transfection efficiency. Therefore, the engineered targeting tLyp-1 exosomes offer a promising gene delivery platform for future cancer therapy.Graphical AbstractThe tLyp-1-lamp2b plasmid transfected HEK293T cells can secreted tumor targeting tLyp-1 exosomes. By electroporation technology, targeting tLyp-1 exosomes were loaded with siRNA. When targeting tLyp-1 exosome ruptured in cytoplasm, siRNA was loaded into the RNA-induced silencing complex (RISC). The sense (passenger) strand was degraded while the a...
Source: Asian Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Source Type: research
In this study, we have found that polyI:C pretreatment prevents caerulein-induced pancreas edema, neutrophil infiltration, the accumulation of ROS, and inflammatory gene expression in the AP mice models. PolyI:C-triggered IFN-β production and downstream IFNAR signaling activation are required for the suppressive effect of polyI:C in the caerulein-induced AP model. Our study has not only demonstrated the protective role of polyI:C in limiting AP, but has also suggested a potential application of TLR3 ligands in the treatment of AP. Materials and Methods Mice and Reagents Ifnb−/− mice and Ifnar1−/&m...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
CAR T cell therapy is a promising new gene therapy to treat cancer offered at a select few hospitals, including OHSU Hospital in Portland. Medicare is considering whether to cover the pricey therapy, which is given for two types of blood cancers. A Eugene oncologist is hoping Medicare will soon cover CAR-T in both the outpatient and in-patient settings. “The technology is evolving so quickly,” said Dr. Jeff Sharman, who also se rves as medical director of hematology research for the US Oncology…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
Xuequn Xu†, J. N. Rashida Gnanaprakasam†, John Sherman† and Ruoning Wang* Center for Childhood Cancer and Blood Diseases, Hematology/Oncology &BMT, The Research Institute at Nationwide Children's Hospital, Ohio State University, Columbus, OH, United States The adoptive transfer of T cells expressing chimeric antigen receptors (CARs) through genetic engineering is one of the most promising new therapies for treating cancer patients. A robust CAR T cell-mediated anti-tumor response requires the coordination of nutrient and energy supplies with CAR T cell expansion and function. Howe...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This is the last week to register at the discounted early registration rates for the 18th MIXiii-BIOMED Conference and Exhibition, taking place May 14-16 at The David InterContinental Hotel, Tel Aviv, Israel. As Israel’s lea...
Source: Medgadget - Category: Medical Devices Authors: Tags: Sponsored Content Source Type: blogs
Conclusion The expression of the components of the PTN-MK-RPTPβ/ζ axis in immune cells and in inflammatory diseases suggests important roles for this axis in inflammation. Pleiotrophin has been recently identified as a limiting factor of metainflammation, a chronic pathological state that contributes to neuroinflammation and neurodegeneration. Pleiotrophin also seems to potentiate acute neuroinflammation independently of the inflammatory stimulus while MK seems to play different -even opposite- roles in acute neuroinflammation depending on the stimulus. Which are the functions of MK and PTN in chronic neuroinfla...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Discussion Suppressor of cytokine signaling 1 is an essential molecule for maintaining immune homeostasis and subverting inflammation. Disorders arising from excess inflammation or SOCS1 deficiency can be potentially treated with SOCS1 mimetics (Ahmed et al., 2015). While SOCS1 has promising potential in many disorders, it should be noted that new targets and actions of SOCS1 are still being discovered and not all the effects of this protein are beneficial in autoimmune diseases and cancer. For instance, SOCS1 degrades IRS1 and IRS2, required for insulin signaling, via the SOCS Box domain, thus, limiting its potential in ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Authors: Chang TMS Abstract It is only in the last 20 years that many of the original ideas on artificial cells are being increasingly applied and extended by researchers around the world. Artificial cell has now evolved into nanomedicine, biotherapeutics, blood substitutes, drug delivery, enzyme/gene therapy, cancer therapy, cell/stem cell therapy, nanoparticles, liposomes, bioencapsulation, replicating synthetic cells, cell encapsulation/scaffold, biosorbent/immunosorbent haemoperfusion/plasmapheresis, regenerative medicine, encapsulated microbe, nanobiotechnology, nanotechnology and other areas. More futu...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Gene Therapy | Genetics | Health | Science | Texas University